Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.

Treatment with AB21 alone had no impact on tumor growth while treatment with anti-PD-1 alone trended toward a delayed tumor growth compared to the PBS control but did not reach statistical significance (Fig. 5 e).

also in 111,027 other papers